Verona Pharma Clinical Trials: 18 Led Studies

Archive historyOct 2022 to Jun 2026

27 recorded changes across Verona Pharma trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 8 of these trials. One is shown below.

Completion date movePrimary completion moved 359 days laterNCT06559150 · recorded 1 Jun 2026

Track to read them

+23 more recorded changes · Track a drug to see every change the night it lands

Start tracking drugs

Most active programmes

The drugs appearing most often across Verona Pharma's recently active trials. Comparator arms are excluded.

RPL5544 trials
Ensifentrine3 trials
Ensifentrine 3 mg2 trials
Glycopyrrolate 42.5 mcg2 trials
Part A: RPL5542 trials
Part B: RPL5542 trials

Upcoming readouts

Next primary completion dates among Verona Pharma's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Aug 2026A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects Wi…Phase 2
Dec 2026Effect of Ensifentrine on Sputum Markers of Inflammation in COPDPhase 2
Sept 2027A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisPhase 2

Top therapeutic areas

Conditions studied most often across Verona Pharma's recently active trials.

Chronic Obstructive Pulmonary Disease6 trials
COPD6 trials
Non-cystic Fibrosis Bronchiectasis1 trial
Cystic Fibrosis1 trial
Pulmonary Disease, Chronic Obstructive1 trial
Chronic Obstructive Pulmonary Disease Moderate1 trial

Verona Pharma trials

The 18 most significant of Verona Pharma's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPDNCT07016412Ensifentrine 3 mg	Phase 2	Locked · track to reveal	OngoingRecruiting	480 est.	5 Aug 2026
Effect of Ensifentrine on Sputum Markers of Inflammation in COPDNCT05270525Ensifentrine	Phase 2	Locked · track to reveal	OngoingRecruiting	56 est.	Dec 2026
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisNCT06559150Nebulized Ensifentrine Suspension; 3 mg	Phase 2	Locked · track to reveal	OngoingRecruiting	284 est.	24 Sept 2027
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary DiseaseNCT07132983Ensifentrine 3 mg	Phase 2	Locked · track to reveal	Completed	33 est.	28 Nov 2025
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPDNCT06545500Glycopyrrolate (85 μg)	Phase 2	Locked · track to reveal	Completed	46 est.	2 Jan 2025
Effect of Ensifentrine Treatment on CAT ScoreNCT06460493Ensifentrine 3 mg twice daily	Phase 3	Locked · track to reveal	Completed	20 est.	26 Nov 2024
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDNCT04535986Ensifentrine	Phase 3	Locked · track to reveal	Completed	763 est.	12 Sept 2022
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDNCT04542057Ensifentrine	Phase 3	Locked · track to reveal	Completed	790 est.	3 May 2022
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary DiseaseNCT04091360Part A: RPL554	Phase 2	Locked · track to reveal	Completed	40 est.	10 Dec 2020
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDNCT03937479Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium	Phase 2	Locked · track to reveal	Completed	416 est.	15 Nov 2019
Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder InhalerNCT04027439Part A: RPL554	Phase 2	Locked · track to reveal	Completed	37 est.	23 May 2019
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPDNCT03673670RPL554 Suspension	Phase 2	Locked · track to reveal	Completed	79 est.	13 Nov 2018
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT03443414RPL554 suspension	Phase 2	Locked · track to reveal	Completed	405 est.	23 Jan 2018
A Study of RPL554 in Patients With Cystic FibrosisNCT02919995RPL554	Phase 2	Locked · track to reveal	Completed	10 est.	3 Nov 2017
The Effects of RPL554 in Addition to Tiotropium in COPD PatientsNCT030281421.5 mg RPL554 plus tiotropium	Phase 2	Locked · track to reveal	Completed	30 est.	Aug 2017
The Effects of RPL554 on Top of Standard COPD Reliever MedicationsNCT02542254Salbutamol	Phase 2	Locked · track to reveal	Completed	36 est.	Dec 2015
Comparison of RPL554 With Placebo and Salbutamol in Asthmatic PatientsNCT02427165RPL554	Phase 2	Locked · track to reveal	Completed	29 est.	Nov 2015
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsNCT02307162RPL554	Phase 1	Locked · track to reveal	Completed	112 est.	Jul 2015

View all trials18

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

Phase 2RecruitingNCT07016412 ↗

Primary completion: Aug 2026; estimated
Enrollment: 480; estimated
Start: Jul 2025; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Ensifentrine 3 mg
Glycopyrrolate 21.25 mcg
Glycopyrrolate 42.5 mcg
Placebo

Brief summary

This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 May 2026

Completion date move · 1

Status change · 1

Track Verona Pharma drugs to see every change the night it lands.

Start tracking drugs

Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

Phase 2RecruitingNCT05270525 ↗

Primary completion: Dec 2026; estimated
Enrollment: 56; estimated
Start: May 2022; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

COPD

Interventions

Ensifentrine
Placebo

Brief summary

This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a total duration of up…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2025

Completion date move · 2

Enrollment change · 1

Status change · 1

Track Verona Pharma drugs to see every change the night it lands.

Start tracking drugs

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Phase 2RecruitingNCT06559150 ↗

Primary completion: Sept 2027; estimated
Enrollment: 284; estimated
Start: Sept 2024; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

Non-cystic Fibrosis Bronchiectasis

Interventions

Nebulized Ensifentrine Suspension; 3 mg
Nebulized Placebo Solution

Brief summary

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jun 2026

Completion date move · 1

Enrollment change · 1

Track Verona Pharma drugs to see every change the night it lands.

Start tracking drugs

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

Phase 2CompletedNCT07132983 ↗

Primary completion: Nov 2025; actual
Enrollment: 33; estimated
Start: Oct 2025; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Ensifentrine 3 mg
Glycopyrrolate 42.5 mcg
Ensifentrine 1.5 mg
Ensifentrine 3 mg (marketed formulation)

Brief summary

This study will assess the pharmacokinetics (PK), pharmacodynamics (PD) and safety of ensifentrine and glycopyrrolate fixed dose (FDC) product, the individual components of the FDC (ensifentrine and glycopyrrolate, each in the FDC formulation), ensifentrine 1.5 mg in the FDC formulation and ensifentrine 3 mg in the…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Feb 2026

Status change · 2

Completion date move · 2

Enrollment change · 1

Track Verona Pharma drugs to see every change the night it lands.

Start tracking drugs

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

Phase 2CompletedNCT06545500 ↗

Primary completion: Jan 2025; actual
Enrollment: 46; estimated
Start: Aug 2024; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Glycopyrrolate (85 μg)
Glycopyrrolate (42.5 μg)
Glycopyrrolate (14 μg)
Placebo

Brief summary

This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice daily via standard jet nebulizer over three 1-week active treatment periods and one 1-week…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jul 2025

Status change · 2

Completion date move · 2

Enrollment change · 1

Track Verona Pharma drugs to see every change the night it lands.

Start tracking drugs

Effect of Ensifentrine Treatment on CAT Score

Phase 3CompletedNCT06460493 ↗

Primary completion: Nov 2024; actual
Enrollment: 20; estimated
Start: Jun 2024; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

COPD

Interventions

Ensifentrine 3 mg twice daily

Brief summary

The purpose of this open-label, single center trial is to assess the effect of twice daily nebulized ensifentrine (3 mg) on COPD symptoms measured by the COPD Assessment Test (CAT™) scores over 12 weeks in subjects with symptomatic, moderate to severe COPD, taking maintenance LAMA/LABA or LAMA/LABA/ICS therapy.…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jul 2025

Status change · 2

Completion date move · 2

Enrollment change · 1

Track Verona Pharma drugs to see every change the night it lands.

Start tracking drugs

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

Phase 2CompletedNCT03937479 ↗

Primary completion: Nov 2019; actual
Enrollment: 416; estimated
Start: May 2019; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

COPD

Interventions

Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium
Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium
Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium
Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium
Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium

Brief summary

The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

Phase 2CompletedNCT03673670 ↗

Primary completion: Nov 2018; actual
Enrollment: 79; estimated
Start: Jul 2018; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

COPD

Interventions

RPL554 Suspension
Placebo
Tiotropium/olodaterol (Respimat)

Brief summary

The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase \[PDE\]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol (Respimat) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

The Effects of RPL554 in Addition to Tiotropium in COPD Patients

Phase 2CompletedNCT03028142 ↗

Primary completion: Aug 2017; actual
Enrollment: 30; estimated
Start: Jan 2017; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

Chronic Obstructive Pulmonary Disease Moderate

Interventions

1.5 mg RPL554 plus tiotropium
6 mg RPL554 plus tiotropium
Placebo plus tiotropium

Brief summary

This is a phase II, randomised, double blind, placebo controlled, complete block, three way crossover study to investigate treatment with nebulised RPL554 and tiotropium together in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The purpose of this study is to assess the bronchodilator…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

The Effects of RPL554 on Top of Standard COPD Reliever Medications

Phase 2CompletedNCT02542254 ↗

Primary completion: Dec 2015; actual
Enrollment: 36; estimated
Start: Oct 2015; Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Salbutamol
Ipratropium
RPL554
Salbutamol matched placebo
Ipratropium matched placebo
RPL554 matched placebo

Brief summary

This study evaluates the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disorder (COPD). All patients will receive the same six treatments in a randomised sequence: 1. salbutamol, 2. ipratropium, 3. salbutamol + RPL554, 4. ipratropium + RPL554, 5. RPL554 6. Placebo

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.